Brain Blend

Related by research scope · open each to compare

Regulatory detail for this region is not available in the current seed.

Transparent blend · bci-1.0 · never paid-placement

Primary name

Brain Blend

Sequence not available in current seed.

• GHS hazard class on file
• PPE & spill response
• Disposal guidance
• Not-for-human-consumption posture

Synthetic anxiolytic heptapeptide derived from immunomodulatory tuftsin; approved in Russia for generalized anxiety and studied for nootropic and neuroprotective effects.

Selank exerts its effects through at least three converging pathways. First, it inhibits plasma enkephalin-degrading enzymes (including enkephalinase and related peptidases), raising circulating and central leucine- and methionine-enkephalin levels and thereby augmenting endogenous opioid-peptidergic tone. Second, it elevates brain-derived neurotrophic factor (BDNF) in the hippocampus and prefrontal cortex, a mechanism linked to its protective effects on cognition under alcohol and stress challenge in rodent models (PMID 31625062). Third, it modulates serotonin metabolism and monoamine turnover, and influences the Th1/Th2 cytokine balance — immunomodulatory effects documented in patients treated for GAD. It is additionally reported to act as an indirect modulator of GABA-A receptor signaling, although this is distinguished mechanistically from benzodiazepine-site binding. Functional connectivity fMRI studies in healthy human volunteers found altered resting-state connectivity between the right amygdala and temporal regions following selank administration, consistent with its reported anxiolytic profile (PMID 32342318).

Molar mass

751.9 g/mol

Synthetic ACTH(4-7)-PGP heptapeptide approved in Russia for ischemic stroke; studied for neuroprotection and cognitive function via BDNF upregulation.

Semax upregulates brain-derived neurotrophic factor (BDNF) and its receptor TrkB transcription, promoting neuronal survival, synaptic plasticity, and axonal growth in ischemic and degenerative models. It modulates catecholaminergic neurotransmission — increasing dopaminergic and serotonergic tone — and attenuates neuroinflammation partly through effects on immune gene expression, including immunoglobulin and chemokine pathways. The peptide also elevates intracellular calcium signalling in rat neurons and alters opioid receptor activity; its primary metabolite Pro-Gly-Pro (PGP) is independently bioactive and accumulates in brain tissue, likely extending functional duration beyond the short plasma half-life of the parent compound.

Molar mass

813.9 g/mol

How much research exists, and of what maturity — never a verdict on whether it works.

Reading the evidence

• Evidence quality and gaps vary by application — see the cited grades above.
• Indexed-article counts span all evidence tiers, not only completed human trials.
• No first-party human-dosing, efficacy, or benefit claims are made here.

Key reviews & evidence-gap sources

• Zozulia et al. 2008 — Selank randomized controlled trial for generalized anxiety disorder and neurasthenia (Zh Nevrol Psikhiatr Im S S Korsakova; PMID 18454096) — COMPONENT-LEVEL (Selank), NOT blend-level. A completed human RCT for Selank alone; does not test Semax or the combined blend.
• Semax intranasal trial in ischemic stroke patients — BDNF elevation (PMID 29798983) — COMPONENT-LEVEL (Semax), NOT blend-level. A trial of 110 stroke patients given intranasal Semax (two 10-day courses, 6000 mcg/day) reported increased plasma BDNF; does not test Selank or the combined blend.
• Intranasal Semax/N-acetyl-Semax improved cognitive function and reduced amyloid load in an APPswe/PS1dE9 transgenic Alzheimer's mouse model (2025) — COMPONENT-LEVEL (Semax), NOT blend-level, and an ANIMAL model — not a human trial. Does not test Selank or the combined blend.

No registered human trials found for this compound.

Status

No registered trials found

Dominant research route: Intranasal (IN)

Primary registered/administered route in humans (Russia); Semax 0.1% and 1% nasal drops registered; Selank 0.15% nasal drops registered; RCTs in stroke and generalized anxiety (component-level — no combined-blend trial exists).

Bioavailability: Intranasal delivery bypasses gastrointestinal peptidase degradation and provides partial direct nose-to-brain transport via olfactory/trigeminal pathways alongside systemic absorption across respiratory mucosa; Semax 0.1% nasal drop ~50 mcg per 0.05 mL drop; Selank's plasma half-life is ~2–3 minutes.

Dominant studied route for both Semax and Selank as registered Russian drug products, each studied independently — Semax 1% is included in the Russian standard for treatment of ischemic stroke; Selank was investigated in an RCT vs benzodiazepines for generalized anxiety disorder/neurasthenia. No study has tested the two peptides administered together.

Listed as a route of administration for Selank on its Wikipedia drugbox; no published human PK study located for either component or the blend by this route.

Bioavailability: No quantitative human bioavailability figures were located from primary sources; IV is listed alongside nasal mucosa in Selank's drugbox without accompanying PK values.

A drugbox-listed route, not a studied one — no sourced human IV PK study exists for either component, and none for the blend.

Not a registered/studied route in the primary literature; appears only in vendor/community guidance as an alternative to intranasal.

Bioavailability: Vendors describe injectable Semax (e.g. 2.5 mg/mL) as offering 'more predictable systemic bioavailability' vs nasal delivery; no peer-reviewed human SC pharmacokinetic data were located.

A community/vendor-reported alternative route; no registered drug product or published human RCT supports SC administration of Selank, Semax, or the blend.

Not studied as a viable route for either component; oral bioavailability is described as effectively zero due to enzymatic degradation.

Bioavailability: Oral bioavailability is effectively zero — gastric and small-intestinal peptidases degrade the peptide on contact. The Pro-Gly-Pro C-terminal extension common to these ACTH(4-10)-derived heptapeptides confers some peptidase resistance (extending plasma half-life vs parent fragments) but not enough for oral delivery.

Oral route is not used in research or registered products for either component; this is a stability observation, not an oral-absorption claim.

Animal & human figures are kept visibly separate so studied animal doses are never misread as human guidance.

Sorted A–Z by vendor — never by price

Weekly median $/mg from the live vendor crawl.

Researched storefront prices, bucketed

p25 $4.45 · median $4.50 · p75 $4.50 · 8 researched vendors

Legit, COA-backed band: $3.75–$4.50/mg.

Value rule: don't just buy the cheapest — a price under $3/mg is a red flag. Pair price with COA and independent-test grade.

Estimated cost of research (10 mg)

Vial (best researched price)

$38

Bacteriostatic water (generic estimate)

$6

Syringes / supplies (generic estimate)

$12

What each test proves — general guidance, plus this compound's researched purity data

Purity on the current market (researched)

Reported third-party HPLC purity for individually-tested Selank and Semax lots ranges from ~98% to 99.6% (e.g. a Janoshik Semax batch reported 99.625%). Combined-blend lots report per-component mass rather than a single purity figure — e.g. Prime Peptides' Janoshik-tested Selank/Semax 20mg blend batch 5052026SSX (23 JUN 2026): Selank 9.93 mg, Semax 9.77 mg, endotoxin pass (independently confirmed on the vendor's own product page).

Independent labs cited for this compound

No FDA-enforced recalls, market withdrawals, or seizure actions specific to Selank, Semax, or a combined 'Selank & Semax' blend were found in FDA recall databases or enforcement reports. Neither peptide is FDA-approved for any use in the United States, so no approved-product recall mechanism applies; grey-market 'research use only' vials sit outside the FDA recall framework. Reported honestly as an empty recall result — none found — not invented.

Buyer red-flag checklist

• Neither Selank nor Semax is FDA-approved for any medical use in the United States; both are sold only as 'research use only' grey-market products.
• Both Selank acetate and Semax nominations were withdrawn from interim 503A Category 2 (per the FDA's own current bulk-substances page); neither currently has an approved 503A compounding pathway, and Semax is separately scheduled for PCAC review in July 2026 for possible Bulks List inclusion — none of this is FDA approval.
• FDA cited aggregation risk, peptide-related impurities, and limited human safety information as rationale for Category 2 placement of both peptides.
• Both peptides are intranasal neuropeptides of Russian origin (Semax registered in Russia; Selank developed at the Institute of Molecular Genetics RAS) with limited independent Western clinical data.
• Grey-market COA fraud is a documented industry-wide concern (secondary sources cite ~15-20% purity discrepancy in grey-market peptide COAs, not Selank/Semax-specific); microgram-dosed intranasal delivery makes a purity miss of that magnitude effectively undetectable without per-vial independent testing.
• No DEA scheduling, but products cannot legally be marketed as drugs or dietary supplements in the US.
• The vendor pool for Selank/Semax is smaller than for more widely-sold research peptides, increasing the proportion of unverified or marketplace-only (vs vendor-direct) sources.
• Cloudiness or particulate matter in a reconstituted vial may indicate degradation, contamination, or aggregation — a stability concern flagged for this peptide class generally.

GMP vs research-grade: the chemistry (SPPS + HPLC + MS) is identical — the difference is the quality system.

Underdosing / mislabeling: No independent-lab aggregate quantifying underdosing/mislabeling prevalence specific to a combined Selank+Semax blend was found. Secondary aggregator reporting cites industry-wide grey-market peptide COA discrepancy estimates around 15–20% (not Selank/Semax-specific, and not independently verified here); a purity miss of that magnitude on microgram-dosed intranasal neuropeptides would be effectively undetectable to a buyer without per-vial independent testing.

• FDA Import Alert 66-40 authorizes Detention Without Physical Examination (DWPE) of drugs from foreign firms that have not demonstrated current Good Manufacturing Practice (CGMP) compliance (charge code DRUG GMPS, FD&C Act §801(a)(3)/§501(a)(2)(B)). This is a generic CGMP alert — not Selank/Semax-specific — but applies to any imported peptide drug substance manufactured by a non-CGMP-verified foreign establishment; confirmed live against the FDA's own import-alert page.66-40
• An RUO label is not an import exemption — CBP judges actual intended use.
• Lyophilized powder is ambient-stable in transit; temperature control needed for > 7-day transit.
• US-warehouse vendors dodge import scrutiny — they cost more but ship more reliably.

Every item dated & sourced

Neither Selank nor Semax is named on the official WADA/USADA Prohibited List. A commercial vendor blog (Real Peptides) argues Semax could fall under S0 (Non-Approved Substances, since it lacks FDA/EMA approval for human therapeutic use) and speculates it 'could' also be argued under S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics) because it influences BDNF — but that source explicitly frames this as an anti-doping panel's hypothetical argument, not a WADA/USADA determination, and has a direct commercial interest in athlete risk-aversion. Neither substance is a GHRP/GHRH or growth-hormone secretagogue (their characterized mechanisms are neurotrophic/BDNF-modulatory and anxiolytic/immunomodulatory, respectively), so an S2 tag is not well-grounded in that category's own definition. Reported here as an unconfirmed, source-flagged inference — not an established WADA listing.

No granted patents identified in current seed. Composition-of-matter coverage is limited given the peptide's synthetic origin.

• IACUC / IRB research context
• RUO buyer responsibilities & documentation
• Veterinary / alternative-use where lawful
• Jurisdiction-aware "who may lawfully obtain"

What people discuss

Reported concerns — discussion, not established effects

Reading caveats

• self-report only
• vendor-affiliated subreddits present
• no controlled trials referenced
• small-sample anecdotes
• route-of-administration confounding
• Direct aggregate discourse naming a two-peptide 'Selank & Semax Blend' product specifically (vs the individual compounds) could not be confirmed via a systematic thread search this pass; themes/concerns draw on a mix of secondary aggregator write-ups and a handful of individually-verified Reddit threads — treat volume/mix as illustrative, not a census.
• The counterfeit/bunk-product signal (reportedConcerns, counterfeitChatter:'med') is anchored to two individually-verified but anecdotal Reddit reports (an Amazon commingled-inventory concern and a single named-vendor bunk-product report), not an aggregate lab or marketplace count — treat as a real but small-sample signal.

Manually researched from reddit, youtube— theme weights are research estimates, not live counts; aggregated & de-identified. No individual posts, quotes, or usernames are ever shown.

Relative research / market volume — populated once the activity stream is wired

Inline tooltips for lyophilized, RUO, EU/mg, SPPS, 503A and more.

Toggle plain-language ↔ scientific in the header.

• How to read a COA
• Free base vs acetate
• Understanding evidence grades

US regulatory status: Research use only. Research use only.

Emitted as JSON-LD: ChemicalSubstance · BreadcrumbList · FAQPage.

• Price-drop & back-in-stock alerts
• Regulatory-change email digest
• Print / share this datasheet